SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RCEL

AVITA Medical, Inc. (NASDAQ:RCEL)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$15.62-$0.37 (-2.31%)
 
Market cap
$388M
Insider Score
Health Score
Analyst consensus
Listed since
May 14, 2012
Market Cap$388.05M+316.5%
Revenue (ttm)$84.68M+17.0%
Net Income-$36.12M+25.6%
EPS-$1.19+34.3%
Shares Out24.84M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume386,982
Open$15.76
Previous Close$15.99
Day's Range$15.50 - $16.26
52-Week Range$3.22 - $18.43
Beta2.01
AnalystsBuy
Price Target$14.33(-8.26%)
Earnings DateFeb 11, 2027

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Address
28159 Avenue Stanford, Valencia, CA, 91355, US
Market Cap
388 million
Employees
226
Industrial Classification
Medical - Devices

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$234.59K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $15.50 (-7.9%)

3 firms rating RCEL in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Distressed
From RCEL’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-2.31%
5 Days
+0.26%
1 Month
+1.30%
6 Months
+241.05%
1 Year
+316.53%

$RCEL stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RCEL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RCEL's directors and management

Net Shares Purchased by Insiders−60k−30k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RCEL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

RCEL Revenue by Segment or Geography

RCEL's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New RCEL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RCEL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RCEL

VTIVanguard Morningstar Total Stock Market ETF$11.51M
VXFVanguard Extended Market ETF$5.51M
IWCiShares Micro-Cap ETF$1.52M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RCEL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
62.17
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Analyst upgrade to Buy, positive clinical trial data showing efficacy, and fair value boost support bullish sentiment on RCEL fundamentals.

Recent Insider Activity

Buys
14
Sells
0
Buy Value
$234.59K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IWCiShares Micro-Cap ETF0.13%

Weight is the stock’s share of each fund’s holdings.